相关实验视频

Updated: Jul 4, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

肺癌相关血栓形成症 (LCART):专注于免疫检查点阻塞

Andriani Charpidou¹, Grigorios Gerotziafas², Sanjay Popat³

¹Third Department of Internal Medicine and Laboratory, Athens Medical School, National and Kapodistrian University of Athens, Sotiria General Hospital, 157 72 Athens, Greece.

|January 26, 2024

概括

癌症相关血栓形成 (CAT) 是肺癌患者常见的并发症,新疗法可能会增加风险. 管理包括基于个体患者的因素和癌症特征的个性化抗凝治疗.

科学领域:

在瘤学瘤学.
血液学血液学血液学
肺部医学肺部医学

背景情况:

癌症相关的血栓形成 (CAT) 是肺癌患者的重大并发症.
肺癌患者面临的血栓形成风险高于其他固体瘤患者.
像免疫疗法这样的新兴疗法可能会增加CAT风险.

研究的目的:

审查肺癌中CAT的流行病学,病理生理学和风险因素.
讨论新的风险评估模型和CAT的管理策略.
在免疫检查点抑制剂和COVID-19流行病的背景下,专注于CAT.

主要方法:

流行病学,病理生理学,风险因素和CAT管理的文献综述.
分析风险评估模型,包括霍拉纳风险评分和遗传因素.
从前性试验中对抗凝血剂进行比较的治疗结果的评估.

主要成果:

肺癌显著增加了所有疾病阶段的血栓形成风险.
低分子量肝素 (LMWHs) 和直接口服抗凝剂 (DOACs) 在门诊患者中显示出可比的疗效.
个性化抗凝药非常重要,考虑到癌症的特点和治疗方法.

结论:

有效管理CAT需要个性化的抗凝策略.
风险分层和新的预测得分有助于在肺癌中控制血栓形成.
在新型疗法和流行病时代,了解CAT是必不可少的.

关键词:

这是一种抗凝血药物.与癌症相关的血栓形成.免疫检查点抑制剂免疫检查点抑制剂肺癌是一种肺癌.静脉血栓塞栓症是一种静脉血栓塞栓.

更多相关视频

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...